Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
The total cost of medicinal provision of regions from the regional budget in 2016 amounted to 70.54 billion rubles. This is stated in the health report for the last year, prepared for the final board of the Ministry of Health, which began at this time.
Sergei Kutsev, the chief freelance geneticist of the Ministry of Health, believes that it is necessary to expand the so-called list of "24 nosologies" containing a list of orphan (rare) diseases, medicines for which can be purchased at the expense of regional budgets.
In the Ministry of Economic Development and Trade of the Russian Federation on April 10, in preparation for the assessment of regulatory impact, a meeting was held to discuss a bill developed by the FAS, which provides for the introduction of a compulsory licensing mechanism.
In Moscow, the 10th Meeting of the International Working Group on Research on Competition in the Pharmaceutical Markets was held. Representatives of the FAS Russia, foreign competition agencies, including South Africa, Brazil, the United States of America, the United States of America and the United States, participated in the key discussion of the meeting on the specifics of the use of antimonopoly policy tools that stimulate the development of competition in the pharmaceutical industry, provision of medicines to the population and the correlation of antimonopoly legislation and patent protection rights of pharmaceutical innovations. Mongolia, Belarus, China, Japan, Austria and India, as well as industry experts.
We regret to inform you that on April 11, 2017, after a long illness, the founder of the Department of Clinical Pharmacology, Corresponding Member, died. RAS, doctor of medical sciences, professor Yury Borisovich Belousov.
In 2017, the list of VED should be approved more than once a year, as it is now, but as new drugs appear. This was announced at the end of December by Deputy Prime Minister Olga Golodets. According to Alla Rudakova, Professor of the Department of Management and Economics of Pharmacy of the St. Petersburg Chemical and Pharmaceutical Academy, this is a fully justified approach.